High-Dose Stereotactic Radiation for Prostate Cancer

Case Comprehensive Cancer Center (Case CCC) logo

Case Comprehensive Cancer Center (Case CCC)

Status

Completed

Conditions

Adenocarcinoma of the Prostate
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage III Prostate Cancer
Recurrent Prostate Cancer
Stage IIB Prostate Cancer

Treatments

Other: laboratory biomarker analysis
Radiation: stereotactic body radiation therapy
Procedure: quality-of-life assessment

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT01664130
CASE1812
NCI-2012-01252 (Registry Identifier)

Details and patient eligibility

About

This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue

Full description

PRIMARY OBJECTIVES: I. To assess treatment related gastrointestinal (GI) and genitourinary (GU) toxicity for patients who undergo SBRT for localized prostate cancer. SECONDARY OBJECTIVES: I. Follow quality of life after SBRT using Expanded Prostate Cancer Index Composite (EPIC) and American Urological Association (AUA) scores. II. Assess biochemical control after high-dose SBRT. OUTLINE: Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-12 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1.5, 4, 8, and 12 months, every 6 months for 4 years, and then annually thereafter.

Enrollment

35 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The patient must have prostate adenocarcinoma proven by histologic diagnosis
  • The patient must have clinical stage T1a-T3b with localized prostate cancer considered low, intermediate, or high risk as defined by the National Comprehensive Cancer Network (NCCN) guidelines; any patient whom is defined as high-risk must undergo screening with computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis as well as bone scan prior to enrollment for staging purposes; low and intermediate risk patients do not require imaging for staging unless they have a focal symptom warranting investigation
  • Performance status - Karnofsky performance status (PS) >= 70
  • Life expectancy of > 5 years, in the opinion of and as documented by the investigator
  • Patients must either already have fiducials already placed within the prostate, or otherwise be candidates for prostate fiducial placement (no bleeding disorders which may cause excessive bleeding with fiducial placement, INR < 2.0).
  • Patients must have prostate-specific antigen (PSA) drawn within the 90 days prior to enrollment
  • Men must agree to use adequate contraception (double barrier method of birth control or abstinence) for the duration of study participation and for 12 months after completing treatment
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

  • Prior treatment toxicities must be resolved to =< grade 1 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
  • Patients who are receiving any other investigational agents
  • Evidence of metastatic disease prior to radiation
  • Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Prior pelvic radiation therapy
  • Patients whom are planned to receive pelvic nodal radiation are excluded
  • Weight > 350 lbs
  • Contraindications to placement of fiducials required for high-precision image guidance (e.g. bleeding disorders which may cause excessive bleeding with placement, requirement for coumadin, international normalized ratio [INR] > 2.0)
  • Patients unable to maintain a full bladder during treatment
  • Previous prostatectomy
  • Inflammatory bowel disease
  • AUA score > 15 in spite of optimal therapy

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

35 participants in 1 patient group

Treatment (SBRT)
Experimental group
Description:
Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-20 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity.
Treatment:
Procedure: quality-of-life assessment
Radiation: stereotactic body radiation therapy
Other: laboratory biomarker analysis

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems